Daptomycin in vitro activity against methicillin-resistant staphylococcus aureus is enhanced by D-cycloserine in a mechanism associated with a decrease in cell surface charge

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4537-4539

  Gasch, O ^a,b,c   Pillai, S K ^a,b   Dakos, J ^a   Miyakis, S ^a,b,d   Moellering Jr , R C ^a,b   Eliopoulos, G M ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFAZOLIN; CYCLOSERINE; CYTOCHROME C; DAPTOMYCIN; FOSFOMYCIN; IMIPENEM; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BINDING ASSAY; CELL SURFACE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SURFACE CHARGE;

EID: 84882335505     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00799-13     Document Type: Article

References (19)

1. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y. Acad. Sci. 1277:139-158.
2. Kullik I, Jenni R, Berger-Bachi B. 1998. Sequence of the putative alanine racemase operon in Staphylococcus aureus: insertional interruption of this operon reduces D-alanine substitution of lipoteichoic acid and autolysis. Gene 219:9-17.
3. Neuhaus FC, Baddiley J. 2003. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol. Mol. Biol. Rev. 67:686-723.
4. Lambert MP, Neuhaus FC. 1972. Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. J. Bacteriol. 110:978-987.
5. Neuhaus FC, Lynch JL. 1964. The enzymatic synthesis of D-alanyl-Dalanine. 3. On the inhibition of D-alanyl-D-alanine synthetase by the antibiotic D-cycloserine. Biochemistry 3:471-480.
6. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK. 2006. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 44:595-597.
7. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing-21st informational supplement. M100-S21. CLSI, Wayne, PA.
8. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2312-2318.
9. Yang SJ, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillinresistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob. Agents Chemother. 54:3161-3169.
10. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. M26-A. NCCLS, Wayne, PA.
11. Rybak MJ, Bailey EM, Lamp KC, Kaatz GW. 1992. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1109-1114.
12. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163.
13. Miro JM, Entenza JM, del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, Giddey M, Armero Y, Pericas JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A. 2012. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillinsusceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 56:4511-4515.
14. Rand KH, Houck HJ. 2004. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48:2871-2875.
15. Snydman DR, McDermott LA, Jacobus NV. 2005. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves. J. Chemother. 17:614-621.
16. Kraus D, Herbert S, Kristian SA, Khosravi A, Nizet V, Gotz F, Peschel A. 2008. The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. BMC Microbiol. 8:85. doi:10 .1186/1471-2180-8- 85.
17. Udekwu KI, Parrish N, Ankomah P, Baquero F, Levin BR. 2009. Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63:745-757.
18. Quinn B, Hussain S, Malik M, Drlica K, Zhao X. 2007. Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J. Antimicrob. Chemother. 60:1380-1383.
19. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672.